{
  "source": "PA-Notification-Dojolvi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1330-6\nProgram Prior Authorization/Notification\nMedication Dojolvi® (triheptanoin)\nP&T Approval Date 10/2020, 10/2021, 10/2022, 10/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nDojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and\nfatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-\nchain fatty acid oxidation disorders (LC-FAOD).\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Dojolvi will be approved based on ALL of the following criteria:\na. Diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD)\n- AND -\nb. Disease has been molecularly confirmed (i.e., genetic testing)\n- AND -\nc. Patient is not receiving Dojolvi in combination with any other medium-chain\ntriglyceride (MCT) products\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Dojolvi will be approved based on all the following criteria:\na. Documentation of positive clinical response to Dojolvi therapy\n- AND -\nb. Patient is not receiving Dojolvi in combination with any other medium-chain\ntriglyceride (MCT) products\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\n© 2025 UnitedHealthcare Services, Inc.\n1\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Dojolvi [package insert]. Novato, CA: Ultragenyx Pharmaceut",
    "e-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Dojolvi [package insert]. Novato, CA: Ultragenyx Pharmaceutical, Inc.; October 2023.\nProgram Prior Authorization/Notification - Dojolvi® ( triheptanoin )\nChange Control\n10/2020 New program\n10/2021 Annual review with no change to clinical coverage criteria. Updated\nreference.\n10/2022 Annual review with no change to clinical coverage criteria. Updated\nreference. Added state mandate footnote.\n10/2023 Annual review with no change to clinical coverage criteria.\n5/2024 Revised initial authorization to 12 months. Updated reference.\n5/2025 Annual review with no change to clinical coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}